Login to Your Account

Ascletis gears up to go public with $20M from Goldman Sachs

By Shannon Ellis
Staff Writer

Wednesday, December 2, 2015

SHANGHAI – Ascletis Pharmaceuticals Co. Ltd. – China's answer to Gilead Sciences Inc. with its own curative HCV treatments in the clinic here – has just received its second tranche of financial backing in almost as many months, but this time around the funds are coming from investment bank, Goldman Sachs.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription